Literature DB >> 28541581

A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies.

Xavier Bossuyt1,2, Niels Rasmussen3, Pieter van Paassen4, Bernard Hellmich5,6, Bo Baslund7, Pieter Vermeersch2,8, Daniel Blockmans1,9, Jan-Willem Cohen Tervaert10, Elena Csernok5,6, Jan Damoiseaux11.   

Abstract

Objective: The objective of this multicentre study was to improve the clinical interpretation of PR3- and MPO-ANCAs as an adjunct for the diagnosis of ANCA-associated vasculitis (AAV) by defining thresholds and test result intervals based on predefined specificities and by calculating test result interval-specific likelihood ratios (LRs).
Methods: Eight different PR3- and MPO-ANCA immunoassays from seven companies were evaluated using 251 diagnostic samples from AAV patients and 924 diseased controls.
Results: Thresholds for antibody levels were determined based on predefined specificities (95, 97.5, 99 and 100%) and used to delimit test result intervals. Test result interval-specific LRs were determined. For all assays, the LR for AAV increased with increasing antibody level. For all but one immunoassay, high antibodies levels (associated with LR >55) were found in a substantial fraction (>65%) of patients. The area under the curve (AUC) of receiver operating characteristics analysis of a diagnostic approach in which positive results were confirmed by IIF or another immunoassay was not substantially higher than the AUC of performing immunoassay only. The highest AUC was found when immunoassay was combined with another immunoassay or with IIF.
Conclusion: To diagnose AAV based on PR3- and MPO-ANCA, it is useful to define thresholds for antibody levels and to assign test result interval-specific LRs. Higher antibody levels are associated with a higher likelihood for disease. Such information improves clinical interpretation.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  ANCA; MPO-ANCA; PR3-ANCA; anti-neutrophil cytoplasmic antibodies; granulomatosis with polyangiitis; microscopic polyangiitis; myeloperoxidase; proteinase-3; vasculitis

Mesh:

Substances:

Year:  2017        PMID: 28541581     DOI: 10.1093/rheumatology/kex170

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

1.  Clinical relevance of ANCA in small-vessel vasculitis: positioning of antigen-specific immunoassays.

Authors:  Jan Damoiseaux; Xavier Bossuyt
Journal:  Clin Rheumatol       Date:  2018-05-25       Impact factor: 2.980

Review 2.  [ANCA-associated vasculitides : State of the art].

Authors:  B Hellmich
Journal:  Z Rheumatol       Date:  2019-08       Impact factor: 1.372

3.  Antineutrophil cytoplasmic antibodies and their relationship with disease activity and presence of staphylococcal superantigens in nasal swabs in patients having granulomatosis with polyangiitis: results of a study involving 115 patients from a single center.

Authors:  Justyna Fijolek; E Wiatr; V Petroniec; E Augustynowicz-Kopec; M Bednarek; D Gawryluk; K Roszkowski-Sliz
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

Review 4.  The perspective on standardisation and harmonisation: the viewpoint of the EASI president.

Authors:  Jan Damoiseaux
Journal:  Auto Immun Highlights       Date:  2020-02-06

5.  Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis.

Authors:  Juliana Goldbaum Crescente; Alessandra Dellavance; Marcio Augusto Diniz; Flair Jose Carrilho; Luis Eduardo Coelho de Andrade; Eduardo Luiz Rachid Cançado
Journal:  Clinics (Sao Paulo)       Date:  2021-02-05       Impact factor: 2.365

Review 6.  Antineutrophil cytoplasmic antibodies (ANCA) - their role in pathogenesis, diagnosis, and treatment monitoring of ANCA-associated vasculitis.

Authors:  Justyna FijoŁek; ElŻbieta Wiatr
Journal:  Cent Eur J Immunol       Date:  2020-07-09       Impact factor: 2.085

7.  Likelihood Ratio Approach and Clinical Interpretation of Laboratory Tests.

Authors:  Walter Fierz; Xavier Bossuyt
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

Review 8.  New concepts in ANCA detection and disease classification in small vessel vasculitis: the role of ANCA antigen specificity.

Authors:  Elena Csernok
Journal:  Mediterr J Rheumatol       Date:  2018-03-19

Review 9.  Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?

Authors:  Zachary S Wallace; John H Stone
Journal:  Front Immunol       Date:  2019-12-06       Impact factor: 7.561

10.  ANCA associated vasculitis.

Authors:  Robert W Hunter; Nicola Welsh; Tariq E Farrah; Peter J Gallacher; Neeraj Dhaun
Journal:  BMJ       Date:  2020-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.